| scholarly article | Q13442814 |
| P50 | author | Baohai Shao | Q37370740 |
| Jenny E Kanter | Q52684544 | ||
| Rebecca A. Haeusler | Q75273899 | ||
| Karin E. Bornfeldt | Q87887672 | ||
| John E Hokanson | Q89513456 | ||
| Janet K Snell-Bergeon | Q107143200 | ||
| Masami Shimizu-Albergine | Q125299270 | ||
| Farah Kramer | Q125299327 | ||
| P2093 | author name string | Jay W Heinecke | |
| Gregory L Kinney | |||
| Shelley Barnhart | |||
| Mark J Graham | |||
| Rosanne M Crooke | |||
| Karol Bomsztyk | |||
| Tomas Vaisar | |||
| Daniel Mar | |||
| Clarence R Manuel | |||
| P2860 | cites work | Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver | Q24300330 |
| Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies | Q24608301 | ||
| The response-to-retention hypothesis of early atherogenesis | Q24629974 | ||
| The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia | Q26864682 | ||
| Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease? | Q28077776 | ||
| Molecular and Cellular Mechanisms of Cardiovascular Disorders in Diabetes | Q28395675 | ||
| Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia | Q28565000 | ||
| Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans | Q28575302 | ||
| Skyline: an open source document editor for creating and analyzing targeted proteomics experiments | Q30080030 | ||
| Loss-of-function mutations in APOC3, triglycerides, and coronary disease | Q30408720 | ||
| Loss-of-function mutations in APOC3 and risk of ischemic vascular disease | Q34425444 | ||
| Very-Low-Density Lipoprotein-Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III. | Q34551430 | ||
| Parallel reaction monitoring (PRM) and selected reaction monitoring (SRM) exhibit comparable linearity, dynamic range and precision for targeted quantitative HDL proteomics | Q34654305 | ||
| Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality | Q35012749 | ||
| Aggressive very low-density lipoprotein (VLDL) and LDL lowering by gene transfer of the VLDL receptor combined with a low-fat diet regimen induces regression and reduces macrophage content in advanced atherosclerotic lesions in LDL receptor-deficien | Q35088381 | ||
| Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles | Q35608640 | ||
| Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia | Q35767718 | ||
| Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1. | Q35849515 | ||
| A Cluster of Proteins Implicated in Kidney Disease Is Increased in High-Density Lipoprotein Isolated from Hemodialysis Subjects | Q36257138 | ||
| Type 1 diabetes promotes disruption of advanced atherosclerotic lesions in LDL receptor-deficient mice. | Q36883079 | ||
| Does Elevated Glucose Promote Atherosclerosis? Pros and Cons | Q37083092 | ||
| A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection | Q37171168 | ||
| ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan | Q37317424 | ||
| Diabetes and atherosclerosis: is there a role for hyperglycemia? | Q37333371 | ||
| Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study | Q37403220 | ||
| Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study | Q37403310 | ||
| Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions | Q37486465 | ||
| Lipoprotein physiology in nondiabetic and diabetic states. Relationship to atherogenesis | Q37548758 | ||
| Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis | Q37711215 | ||
| Cholesterol efflux: a novel regulator of myelopoiesis and atherogenesis. | Q38053137 | ||
| Hypercholesterolemia links hematopoiesis with atherosclerosis. | Q38066291 | ||
| Insulin resistance and hyperglycaemia in cardiovascular disease development | Q38198953 | ||
| Insulin stimulates hepatic low density lipoprotein receptor-related protein 1 (LRP1) to increase postprandial lipoprotein clearance | Q38360290 | ||
| A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels | Q38616263 | ||
| Recommendation on Design, Execution, and Reporting of Animal Atherosclerosis Studies: A Scientific Statement From the American Heart Association | Q38669204 | ||
| ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. | Q39614082 | ||
| The relationship of blood glucose with cardiovascular disease is mediated over time by traditional risk factors in type 1 diabetes: the DCCT/EDIC study | Q40121355 | ||
| Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity | Q40244307 | ||
| Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes | Q40246024 | ||
| Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. | Q40301333 | ||
| Targeting APOC3 in the familial chylomicronemia syndrome | Q41731850 | ||
| Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes | Q42180113 | ||
| Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study | Q43435231 | ||
| Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia | Q46112189 | ||
| Apolipoprotein C-III inhibits triglyceride hydrolysis by GPIHBP1-bound LPL. | Q46300109 | ||
| Inflammatory stimuli induce acyl-CoA thioesterase 7 and remodeling of phospholipids containing unsaturated long (≥C20)-acyl chains in macrophages. | Q46381890 | ||
| Aggravated restenosis and atherogenesis in ApoCIII transgenic mice but lack of protection in ApoCIII knockouts: the effect of authentic triglyceride-rich lipoproteins with and without ApoCIII. | Q46702771 | ||
| FoxO transcription factors are required for hepatic HDL-cholesterol clearance | Q50163221 | ||
| Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes. | Q51716105 | ||
| Multi-dimensional Transcriptional Remodeling by Physiological Insulin In Vivo. | Q64957324 | ||
| Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein | Q68819183 | ||
| Metabolism of C-apolipoproteins: kinetics of C-II, C-III1 and C-III2, and VLDL-apolipoprotein B in normal and hyperlipoproteinemic subjects | Q71045910 | ||
| Acute phase reactants of mice. I. Isolation of serum amyloid P-component (SAP) and its induction by a monokine | Q71606610 | ||
| Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels | Q72575250 | ||
| ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan biglycan | Q78432641 | ||
| Metabolic Karma-The Atherogenic Legacy of Diabetes: The 2017 Edwin Bierman Award Lecture | Q88426325 | ||
| Effects of APOC3 Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism | Q90724347 | ||
| ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance | Q92050948 | ||
| PIXUL-ChIP: integrated high-throughput sample preparation and analytical platform for epigenetic studies | Q92709500 | ||
| Serum apolipoproteins and apolipoprotein-defined lipoprotein subclasses: a hypothesis-generating prospective study of cardiovascular events in T1D | Q92774530 | ||
| P921 | main subject | type-1 diabetes | Q124407 |
| P304 | page(s) | 4165-4179 | |
| P577 | publication date | 2019-07-11 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Increased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes | |
| P478 | volume | 130 |
| Q99593566 | A New Treatment Strategy for Diabetic Dyslipidemia? |
| Q96818381 | Metformin Decreases Insulin Resistance in Type 1 Diabetes Through Regulating p53 and RAP2A in vitro and in vivo |
| Q89967822 | Monocytes and Macrophages as Protagonists in Vascular Complications of Diabetes |
| Q90539112 | Remnants of the Triglyceride-Rich Lipoproteins, Diabetes, and Cardiovascular Disease |
Search more.